• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content

Loading…

Flash Player 9 (or above) is needed to view presentations.
We have detected that you do not have it on your computer. To install it, go here.

Like this presentation? Why not share!

Toward an integrated view on the molecular control of cell behaviour, molecular pharmacology and toxicology in an organ specific context

on

  • 2,012 views

Description of Vivomicx activities

Description of Vivomicx activities
a detailed analyses of the molecular make up of predestined cell subsets in their physiological and pathophysiological conditions in vivo

Statistics

Views

Total Views
2,012
Views on SlideShare
2,008
Embed Views
4

Actions

Likes
1
Downloads
0
Comments
0

2 Embeds 4

http://www.slideshare.net 3
http://www.linkedin.com 1

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Toward an integrated view on the molecular control of  cell behaviour, molecular pharmacology and toxicology  in an organ specific context Toward an integrated view on the molecular control of cell behaviour, molecular pharmacology and toxicology in an organ specific context Presentation Transcript

    • Vivomicx - nature meets nurture - Toward an integrated view on the molecular control of cell behaviour, molecular pharmacology and toxicology in an organ specific context Vivomicx
    • Expenses of drug development increased dramatically in recent years Frantz, Nat Rev Drug Disc, Nov 2003 Vivomicx
    • In parallel, the number of drugs submitted to and approved by the FDA / EMEA dropped dramatically Nat Rev Drug Disc May 2004 Vivomicx
    • Innovations in in vivo pharmacology will guide success of drug development in the 21st century 2007 status: drop out of drugs in clinical testing due to • lack of efficacy • unexpected toxicity To reduce attrition rate, and get better drugs faster • identify true pharmacology and toxicology of drugs in the development pipeline, at an early stage Vivomicx
    • The drug development paradox Drugs have highly specific pharmacological targets in subsets of cells in diseased organs Pharmacological read-outs employed are often highly non-specific Innovation in in vivo pharmacological read out is prerequisite for successful drug development Vivomicx
    • We look deeper! • At Vivomicx we are able to unravel the processes that play a role on a cellular level in vivo • Our strategy proved that some processes play an important role at a cellular level, but indications did not show when the whole organ is studied at a whole • By providing more information we can help to design better drugs and drug treatment schedules • We can also provide better insight why drugs look good in preclinical studies but fail at a later stage • We provide additional security that your drug will make it through the clinical development! Vivomicx
    • The complexity of life nucleus cell membrane mitochondrion cell organ organism Vivomicx
    • The complexity of life (an example) nucleus cell membrane mitochondrion colon cancer and its metastasis tumor cell organism Vivomicx
    • Anti-angiogenic therapies can stop solid tumor outgrowth Expansion of tumor Blood flow blocking therapy results in tumor supported by angiogenesis In situ tumor size reduction adapted from Folkman, 1996, Sci. Am. Vivomicx
    • Anti-angiogenic therapy - back to the bench - But human tumors are more Animals can be cured complex cell systems www.pathology.ubc.ca www.epitomics.com Vivomicx
    • Understanding tumor vascular cell behaviour • the microenvironment determines cell behaviour • each tumor creates its own microenvironment • within a tumor, different microenvironments exist Vivomicx
    • Vivomicx - nature meets nurture - A unique new strategy to identify the molecular control of cell behaviour, and molecular pharmacology and toxicology in an organ specific context Vivomicx
    • New In vivo pharmacology strategy to guide success of drug development in the 21st century Human, mouse tissues Kinome Transcriptome Proteome microdissection of cell subset of interest healthy / diseased / drug treated Vivomicx
    • In vivo human endothelial gene expression and epigenetics ICAM-1 promotor bisulfite sequencing in microdissected human colon ca endothelial cells Hellebrekers et al, CancRes 2006 Vivomicx
    • Cell specific pharmacology of targeted drugs unmasked whole organ analysis target cell analysis 12 20 * 10 15 8 6 10 VCAM-1 4 rel. gene expression 5 2 0 0 35 30 * 30 25 25 20 20 MCP-1 15 15 10 10 5 5 0 0 - - - + + tre d ed tre d ed - + + e e as at as at se Vivomicx se di di Adapted from Asgeirsdotttir, Molema et al, submitted
    • Vivomicx - nature meets nurture - Revealing the true pharmacological identity of new molecular entities for successful development of the drugs of the future Vivomicx Groningen, The Netherlands Business Development: Jan W. Zuidema Tel. +31 593-370006 E-mail: info@4vmarketing.com Vivomicx